Vt. to get $1.1 million drug settlement
The complaint accuses GlaxoSmithKline LLC of engaging in unfair and deceptive practices by misrepresenting Avandia's cardiovascular risks and safety profile.
Vermont Attorney General William Sorrell said Thursday that GlaxoSmithKline has reached a $90 million settlement with 37 other attorneys general and has agreed to change how it markets and promotes diabetes drugs.
TALK TO US
If you'd like to leave a comment (or a tip or a question) about this story with the editors, please email us. We also welcome letters to the editor for publication; you can do that by filling out our letters form and submitting it to the newsroom.